Wantai serology and molecular kits for screening and confirmation of COVID-19.
Infection with HEV causes acute sporadic and epidemic viral hepatitis and induces acute or subclinical liver diseases similar to Hepatitis A. Hepatitis E can be detected using Beijing Wantai’s diagnostic products.
The human immunodeficiency virus, commonly referred to as HIV, attacks the body’s immune system, which can lead to immune deficiency. Our ELISA, rapid and confirmation tests can be used to detect HIV.
The human T-cell lymphotropic viruses HTLV 1 & HTLV 2 are transmitted transplacentally, parenterally, sexually and by infected blood. Our ELISA test detects antibodies to both HTLV 1 and/or 2.
Infection with the hepatitis B virus causes both acute and chronic hepatitis. We produce ELISA and rapid tests that identify the different serological markers expressed during the three phases of the disease.
The Hepatitis C virus is a blood borne virus primarily transmitted by blood transfusion which can cause Hepatitis C in acute (asymptomatic) and chronic form. HCV can be detected using our ELISA, rapid and confirmation tests.
The human enterovirus 71 (EV71) is a common cause for hand, foot and mouth disease and is sometimes associated with severe central nervous system diseases. Our ELISA and rapid test can detect EV71.
Caused by the Spirochete bacterium Treponema pallidum, Syphilis is primarily sexually transmitted, during pregnancy or by blood transfusion. Our ELISA and rapid tests can be used to detect Syphilis.
Tuberculosis is an infectious disease which is spread from person to person through the air by coughing, sneezing or otherwise transmitted saliva. Our ELISA test can be used to detect a TB infection.
Leading the Way in Infectious Disease Diagnostics
We are committed to providing innovative solutions for diagnosing infectious diseases and aim to increase the availability of high-quality vaccines in order to combat infectious diseases globally. We have developed ELISA and PCR kits, and rapid tests for infectious diseases including Hepatitis E – a disease we are committed to combat using Hecolin®, the world’s first vaccine for Hepatitis E, developed by our subsidiary Innovax.
Along with the spreading global pandemic of COVID-19, countries around the world have been struggling to diagnose and control this disease in time. Xiamen University and Wantai have jointly developed innovative, highly sensitive and specific serological and molecular assays for testing of Covid-19.